120 related articles for article (PubMed ID: 16518428)
1. Long-term stability of a patient-convenient 1 mg/ml suspension of tacrolimus for accurate maintenance of stable therapeutic levels.
Elefante A; Muindi J; West K; Dunford L; Abel S; Paplham P; Brown K; Hahn T; Padmanabhan S; Battiwalla M; McCarthy PL
Bone Marrow Transplant; 2006 Apr; 37(8):781-4. PubMed ID: 16518428
[TBL] [Abstract][Full Text] [Related]
2. Practical considerations in the use of tacrolimus for allogeneic marrow transplantation.
Przepiorka D; Devine S; Fay J; Uberti J; Wingard J
Bone Marrow Transplant; 1999 Nov; 24(10):1053-6. PubMed ID: 10578154
[TBL] [Abstract][Full Text] [Related]
3. First clinical experience with the new once-daily formulation of tacrolimus.
First MR
Ther Drug Monit; 2008 Apr; 30(2):159-66. PubMed ID: 18367975
[TBL] [Abstract][Full Text] [Related]
4. Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients.
Alloway R; Steinberg S; Khalil K; Gourishankar S; Miller J; Norman D; Hariharan S; Pirsch J; Matas A; Zaltzman J; Wisemandle K; Fitzsimmons W; First MR
Transplantation; 2007 Jun; 83(12):1648-51. PubMed ID: 17589351
[TBL] [Abstract][Full Text] [Related]
5. Effect of oral itraconazole on the pharmacokinetics of tacrolimus in a hematopoietic stem cell transplant recipient with CYP3A5*3/*3.
Nara M; Takahashi N; Miura M; Saitoh H; Kagaya H; Sawada K
Am J Hematol; 2010 Aug; 85(8):634-5. PubMed ID: 20568249
[No Abstract] [Full Text] [Related]
6. Cortical blindness and seizures in a patient receiving FK506 after bone marrow transplantation.
Steg RE; Kessinger A; Wszolek ZK
Bone Marrow Transplant; 1999 May; 23(9):959-62. PubMed ID: 10338054
[TBL] [Abstract][Full Text] [Related]
7. Calcineurin-inhibitor-induced pain syndrome after a second allogeneic bone marrow transplantation for a child with aplastic anemia.
Nishikawa T; Okamoto Y; Tanabe T; Shinkoda Y; Kodama Y; Tsuru Y; Kawano Y
Pediatr Transplant; 2009 Aug; 13(5):641-4. PubMed ID: 18785910
[TBL] [Abstract][Full Text] [Related]
8. Toxic serum levels of tacrolimus after topical administration in an infant with severe cutaneous graft-versus-host disease.
Prot-Labarthe S; Therrien R; Champagne MA; Duval M; Joubert C
Bone Marrow Transplant; 2007 Aug; 40(3):295-6. PubMed ID: 17549052
[No Abstract] [Full Text] [Related]
9. Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients.
Florman S; Alloway R; Kalayoglu M; Punch J; Bak T; Melancon J; Klintmalm G; Busque S; Charlton M; Lake J; Dhadda S; Wisemandle K; Wirth M; Fitzsimmons W; Holman J; First MR
Transplantation; 2007 Jun; 83(12):1639-42. PubMed ID: 17589349
[TBL] [Abstract][Full Text] [Related]
10. [Tacrolimus ointment in the treatment of chronic cutaneous graft-versus-host disease].
Firmin D; Karam A; Guillerm G; Roguedas AM; Berthou C; Misery L
Ann Dermatol Venereol; 2008 Mar; 135(3):234-6. PubMed ID: 18374862
[No Abstract] [Full Text] [Related]
11. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference.
Wallemacq P; Armstrong VW; Brunet M; Haufroid V; Holt DW; Johnston A; Kuypers D; Le Meur Y; Marquet P; Oellerich M; Thervet E; Toenshoff B; Undre N; Weber LT; Westley IS; Mourad M
Ther Drug Monit; 2009 Apr; 31(2):139-52. PubMed ID: 19177031
[TBL] [Abstract][Full Text] [Related]
12. Interindividual variation of maximal blood levels of tacrolimus after its oral administration in hematopoietic cell transplant recipients.
Yamazaki R; Mori T; Aisa Y; Kato J; Nakamura Y; Nakazato T; Mihara A; Ikeda Y; Okamoto S
Transplant Proc; 2009 Jun; 41(5):1831-3. PubMed ID: 19545738
[TBL] [Abstract][Full Text] [Related]
13. Oral graft vs. host disease in children--treatment with topical tacrolimus ointment.
Albert MH; Becker B; Schuster FR; Klein B; Binder V; Adam K; Nienhoff C; Führer M; Borkhardt A
Pediatr Transplant; 2007 May; 11(3):306-11. PubMed ID: 17430488
[TBL] [Abstract][Full Text] [Related]
14. Intravenous cyclosporine and tacrolimus caused anaphylaxis but oral cyclosporine capsules were tolerated in an allogeneic bone marrow transplant recipient.
Takamatsu Y; Ishizu M; Ichinose I; Ogata K; Onoue M; Kumagawa M; Suzumiya J; Tamura K
Bone Marrow Transplant; 2001 Aug; 28(4):421-3. PubMed ID: 11571519
[TBL] [Abstract][Full Text] [Related]
15. The consequences of tacrolimus blood concentrations during the four weeks following marrow transplantation from an unrelated donor: a single-center experience.
Muta T; Kato K; Gondo H; Oku S; Okeda A; Kamo M; Nawata R; Takase K; Arima F; Shibuya T; Eto T
Gan To Kagaku Ryoho; 2008 Jan; 35(1):99-104. PubMed ID: 18195535
[TBL] [Abstract][Full Text] [Related]
16. A 6-month, multicenter, single-arm pilot study to evaluate the efficacy and safety of generic tacrolimus (TacroBell) after primary renal transplantation.
Kim SJ; Huh KH; Han DJ; Moon IS; Kim SJ; Kim YL; Kim HC; Lee S; Kang CM; Cho BH; Kim YS
Transplant Proc; 2009 Jun; 41(5):1671-4. PubMed ID: 19545705
[TBL] [Abstract][Full Text] [Related]
17. Modified-release tacrolimus.
Chisholm MA; Middleton MD
Ann Pharmacother; 2006 Feb; 40(2):270-5. PubMed ID: 16449540
[TBL] [Abstract][Full Text] [Related]
18. Stability of an alternative extemporaneous captopril fast-dispersing tablet formulation versus an extemporaneous oral liquid formulation.
Pabari RM; McDermott C; Barlow J; Ramtoola Z
Clin Ther; 2012 Nov; 34(11):2221-9. PubMed ID: 23149007
[TBL] [Abstract][Full Text] [Related]
19. Blood tacrolimus concentrations in bone marrow transplant patients undergoing plasmapheresis.
Hale GA; Reece DE; Munn RK; Kniska AB; Phillips GL
Bone Marrow Transplant; 2000 Feb; 25(4):449-51. PubMed ID: 10723590
[TBL] [Abstract][Full Text] [Related]
20. Long-term use of topical tacrolimus (FK506) in high-risk penetrating keratoplasty.
Dhaliwal JS; Mason BF; Kaufman SC
Cornea; 2008 May; 27(4):488-93. PubMed ID: 18434855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
